Abstract

Leucine-rich repeat kinase 2 (LRRK2) variants associated with Parkinson's disease (PD) and Crohn's disease lead to increased phosphorylation of its Rab substrates. While it has been recently shown that perturbations in cellular homeostasis including lysosomal damage can increase LRRK2 activity and localization to lysosomes, the molecular mechanisms by which LRRK2 activity is regulated have remained poorly defined. We performed a targeted siRNA screen to identify regulators of LRRK2 activity and identified Rab12 as a novel modulator of LRRK2-dependent phosphorylation of one of its substrates, Rab10. Using a combination of imaging and immunopurification methods to isolate lysosomes, we demonstrated that Rab12 is actively recruited to damaged lysosomes and leads to a local and LRRK2-dependent increase in Rab10 phosphorylation. PD-linked variants, including LRRK2 R1441G and VPS35 D620N, lead to increased recruitment of LRRK2 to the lysosome and a local elevation in lysosomal levels of pT73 Rab10. Together, these data suggest a conserved mechanism by which Rab12, in response to damage or expression of PD-associated variants, facilitates the recruitment of LRRK2 and phosphorylation of its Rab substrate(s) at the lysosome.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files; source data files for western blots have been provided for all figures.

Article and author information

Author details

  1. Xiang Wang

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Xiang Wang, is an employee of Denali Therapeutics..
  2. Vitaliy V Bondar

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Vitaliy V Bondar, was an employees of Denali Therapeutics when these studies were conducted and is currently an employee of REGENEXBIO Inc..
  3. Oliver B Davis

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Oliver B Davis, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3622-8651
  4. Michael T Maloney

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Michael T Maloney, is an employee of Denali Therapeutics..
  5. Maayan Agam

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Maayan Agam, is an employee of Denali Therapeutics..
  6. Marcus Y Chin

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Marcus Y Chin, is an employee of Denali Therapeutics..
  7. Audrey Cheuk-Nga Ho

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Audrey Cheuk-Nga Ho, was an employee of Denali Therapeutics when these studies were conducted and is currently an employee of Cellares..
  8. Rajarshi Ghosh

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Rajarshi Ghosh, is an employee of Denali Therapeutics..
  9. Dara E Leto

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Dara E Leto, is an employee of Denali Therapeutics..
  10. David Joy

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    David Joy, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9941-9538
  11. Meredith EK Calvert

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Meredith EK Calvert, is an employee of Denali Therapeutics..
  12. Joseph W Lewcock

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Joseph W Lewcock, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3012-7881
  13. Gilbert Di Paolo

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Gilbert Di Paolo, is an employee of Denali Therapeutics..
  14. Robert G Thorne

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Robert G Thorne, is an employee of Denali Therapeutics..
  15. Zachary K Sweeney

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Zachary K Sweeney, was an employee of Denali Therapeutics when these studies were conducted and is currently an employee of Interline Therapeutics Inc..
  16. Anastasia G Henry

    Denali Therapeutics, South San Francisco, United States
    For correspondence
    henry@dnli.com
    Competing interests
    Anastasia G Henry, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8124-5477

Funding

No external funding was received for this work.

Reviewing Editor

  1. Shaeri Mukherjee, University of California, San Francisco, United States

Version history

  1. Preprint posted: February 22, 2023 (view preprint)
  2. Received: February 24, 2023
  3. Accepted: October 23, 2023
  4. Accepted Manuscript published: October 24, 2023 (version 1)
  5. Version of Record published: December 8, 2023 (version 2)

Copyright

© 2023, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,467
    views
  • 450
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xiang Wang
  2. Vitaliy V Bondar
  3. Oliver B Davis
  4. Michael T Maloney
  5. Maayan Agam
  6. Marcus Y Chin
  7. Audrey Cheuk-Nga Ho
  8. Rajarshi Ghosh
  9. Dara E Leto
  10. David Joy
  11. Meredith EK Calvert
  12. Joseph W Lewcock
  13. Gilbert Di Paolo
  14. Robert G Thorne
  15. Zachary K Sweeney
  16. Anastasia G Henry
(2023)
Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes
eLife 12:e87255.
https://doi.org/10.7554/eLife.87255

Share this article

https://doi.org/10.7554/eLife.87255

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Cell Biology
    Yoko Nakai-Futatsugi, Jianshi Jin ... Masayo Takahashi
    Research Article

    Retinal pigment epithelium (RPE) cells show heterogeneous levels of pigmentation when cultured in vitro. To know whether their color in appearance is correlated with the function of the RPE, we analyzed the color intensities of human-induced pluripotent stem cell-derived RPE cells (iPSC-RPE) together with the gene expression profile at the single-cell level. For this purpose, we utilized our recent invention, Automated Live imaging and cell Picking System (ALPS), which enabled photographing each cell before RNA-sequencing analysis to profile the gene expression of each cell. While our iPSC-RPE were categorized into four clusters by gene expression, the color intensity of iPSC-RPE did not project any specific gene expression profiles. We reasoned this by less correlation between the actual color and the gene expressions that directly define the level of pigmentation, from which we hypothesized the color of RPE cells may be a temporal condition not strongly indicating the functional characteristics of the RPE.